Safety and Efficacy of the Xanomeline Transdermal Therapeutic System (TTS) in Patients with Mild to Moderate Alzheimers Disease. · Phase II
705 (USA) · Dr. Muller
consented 2013-11-28
AEs
3
Serious
0
Dropout signal
–
Adverse events
moderate
assessed
Moderate EXCORIATION — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-30 (study day 64.0); relationship: PROBABLE
mild
assessed
Mild PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-30 (study day 64.0); relationship: POSSIBLE
moderate
assessed
Moderate PRURITUS — outcome: NOT RECOVERED/NOT RESOLVED; onset 2014-01-30 (study day 64.0); relationship: POSSIBLE
Data queries
No data queries.